Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase (Q42863913)

8 November 2017

Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase (English)

1 reference

8 November 2017

Séverine Roger

1

1 reference

8 November 2017

Jérôme Paysant

2

1 reference

8 November 2017

Cécile Badier-Commander

3

1 reference

8 November 2017

Alex Cordi

4

1 reference

8 November 2017

Tony J Verbeuren

5

1 reference

8 November 2017

Michel Félétou

6

1 reference

8 November 2017

7 October 2010

1 reference

8 November 2017

Vascular Pharmacology

1 reference

8 November 2017

53

1 reference

8 November 2017

5-6

1 reference

8 November 2017

281-287

1 reference

Studies on inhibition of human platelet function by sodium nitroprusside. Kinetic evaluation of the effect on aggregation and cyclic nucleotide content

8 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Potentiation of platelet aggregation by atrial natriuretic peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Genetic mouse models of the NO receptor 'soluble' guanylyl cyclases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Nitric oxide stimulates the phosphorylation of rap1b in human platelets and acts synergistically with iloprost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

An enzyme-linked receptor mechanism for nitric oxide-activated guanylyl cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Probing the presence of the ligand-binding haem in cellular nitric oxide receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

NO- and haem-independent soluble guanylate cyclase activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Human prostacyclin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

NO-independent, haem-dependent soluble guanylate cyclase stimulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

NO-independent regulatory site on soluble guanylate cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2010.09.008

10.1016/J.VPH.2010.09.008

7 January 2021

Identifiers

DOI

1 reference

8 November 2017

1 reference